CTIS2022-500764-35-00招募中1 期
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS - IFG-01-2022
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- •Indication for treatment with ribociclib in combination with endocrine therapy in the locally advanced or 1st line metastatic therapy setting according to SmPC. (Previous treatment with CDK4/6 inhibitors is allowed in the adjuvant setting), Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures, Written informed consent prior to beginning of trial specific procedures, Subject must be female and aged = 18 years on the day of signing informed consent, Locally advanced or metastatic breast cancer not amenable to curative treatment, Patient has HER2-negative breast cancer confirmed by local laboratory defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0 or 1+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required to confirm the HER2-negative status (based on the most recently analyzed tissue sample tested by a local laboratory, Histologically confirmed ER positive and/ or PgR positive breast cancer determined by core biopsy according to local in-house standard, QTcF interval < 450 ms, Adequate organ function amenable for treatment with ribociclib as assessed by local laboratory, Women of childbearing potential must have a negative urine or serum pregnancy test within 72 h prior to study entry and be willing to use highly effective method of contraception for course of the trial through 21 days after the last dose of trial treatment
排除标准
- •Concurrent participation in a study with an investigational agent/device or within 14 days of study entry or 5 half-lives of the respective investigational agent/device, whichever is longer, Patients who are not treated for advanced HRpos/HER2neg breast cancer in the first line therapy setting, Patients not eligible for treatment with ribociclib according to SmPC or investigator’s discretion, Patients who are pregnant or lactating, Patients with existing or patients who are at significant risk of developing QTc prolongation. This includes patients with long QT syndrome, uncontrolled or significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmia, electrolyte abnormalities, Patients with known hypersensitivity to the active substance of ribociclib, soya, peanut or any other of the excipients of ribociclib, Patients with active systemic infections (for example, bacterial infection requiring intravenous antibiotics at time of initiating study treatment, fungal infection, or detectable viral infection requiring systemic therapy) or viral load (such as known human immunodeficiency virus positivity or with known active hepatitis B or C, for example, hepatitis B surface antigen positive), Patients with serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (such as severe renal impairment, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn’s disease or ulcerative colitis or a preexisting chronic condition resulting in clinically significant diarrhea), Patients who do not agree to collection of biospecimens samples (blood, stool, tissue)
研究者
相似试验
已完成
不适用
Research on clinical development of a new clinical outcome (major pathological response) for preoperative treatment of lung cancer using artificial intelligenceon-small cell lung cancer patients who received preoperative treatment at our hospital from April 2002 to April 2021 and subsequently underwent surgeryJPRN-UMIN000047486Shizuoka Cancer Center50
招募中
2 期
A Phase II/III, Observer-blind, Multi-centre, RandomizedClinical Trial to Evaluate Immunogenicity and Safety of BBV87, anInactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of AgeCTRI/2021/09/036179Bharat Biotech International Ltd
未知
不适用
A PHASE 2, RAMDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF TWO DOSES OF FAVIPIRAVIR IN ADULT PATIENTS WITH UNCOMPLICATED INFLUENZAPER-060-11Toyama Chemical Co., Ltd.,89
已完成
不适用
A Phase 1/1b Open-Label, Multicenter, to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN 2787 in Participants with BRAF and/or NRAS Mutation positive Solid TumorsAny unresectable and locally advanced or metastatic solid tumorsadvanced tumorsSolid tumors10040900NL-OMON56188Kinnate Biopharma10
尚未招募
4 期
Post-Market Clinical Follow-up study of Altiusâ?¢ Buechel Pappas Primary Total Knee Replacement System (Co-Cr Mobile Bearing Knee- Cemented)CTRI/2022/03/041096TTK Healthcare Ltd Ortho Division